We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Merin, director of the leukemia program at Cedars-Sinai ...
In this video, Douglas Tremblay, MD, discusses the results of a study into a first-line treatment of chronic myelomonocytic leukemia presented at ESMO Congress 2024. Tremblay, an assistant professor ...
– Complete remission (CR) rate of 50% and overall response rate (ORR) of 66.7% in 18 evaluable patients with CMML treated with IO-202 in combination with azacitidine – – CR rate of 83.3% and ORR of ...
Phase 1a of the trial examined dose escalation of IO-202 as a monotherapy and in combination with azacitidine. Phase 1b of the trial studied dose expansion data of IO-202 in combination with ...
BOSTON, Dec. 2, 2024 /PRNewswire/ -- Solu Therapeutics ("Solu Therapeutics" or "Solu"), a biotechnology company pioneering novel therapies to eliminate disease-driving cells in cancer, immunology, and ...
CR or mCR in 86% of patients within the first 12 months - Venetoclax-resistant secondary AML transformed from CMML responds to lenzilumab BURLINGAME, CA / ACCESS Newswire / November 4, 2025 / Taran ...
BEXAR COUNTY, Texas – These days, rising costs are not only a reality for everyday necessities. The cost of health care, including the life-saving treatment for various blood cancers, has also been on ...
BOSTON, Dec. 9, 2024 /PRNewswire/ -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback